The present invention is related to a gel formula that contains Pirfenidone, which offers advantages over other pharmaceutical forms of known cutaneous administration in the state of the technique.
The 5-methyl-1-phenyl-2(1H)-pyridone, formula;
It is a drug that has been applied in the restoration of tissues with lesions with fibrosis and the prevention of fibrotic lesions. This compound, Pirfenidone, it is by itself a known compound and its pharmacological effects has been described, for example, in Japanese applications numbers 87677/1974 and 1284338/1976, as an anti-inflammatory agent that includes antipyretic and analgesics. The U.S. Pat. Nos. 3,839,346, published Oct. 1, 1974; the U.S. Pat. No. 3,974,281, published Aug. 10, 1976; the U.S. Pat. No. 4,042,699 published Aug. 16, 1977, and the U.S. Pat. No. 4,052,509 published Oct. 4, 1977, which described the methods for the obtained Pirfenidone, as well as its use as an anti-inflammatory agent. In the Mexican patent 182, 266 the antifibrotic activity of the 5-methyl-1-phenyl-2(1H)-pyridone is described.
Different resources and treatments have been used to the date and none of them have shown to be really effective. Pirfenidone has shown its efficacy as an anti-fibrotic agent in different pathologies and organs, and has been demonstrated in previous works, where we have observed an effect on the fibroblasts and the production of collagen and extracellular matrix, as well as in experimental models and in clinical tests also.
Many substances could form gels when a gelificant agent is added. This is use in many diverse products in the manufacturing industry, from food to paint, passing through adhesives.
Gels are also important in the chemistry part related with the processes SOL_GEL and in the synthesis of solid materials with nanopores.
Gels are classified in: aqueous (hydrogels) or organic (organogels), dependingo if the aqueous component is water or an organic solvent; organic or inorganic in nature, colloidal or thick grain, according to the size of the particles; and rigid gels, elastic or tixothrophic, according to its mechanic properties.
The hydrocolloids are substances that are produced from vegetable and animal proteins or multiple sugars. They have the capacity to swell themselves and to bind to water. The hydrocolloids are used to thicken, solidify and stabilize food.
The object of the present invention is to provide a gel composition for its cutaneous administration that contains Pirfenidone, a viscous agent; a solubilizer; a non ionic solubilizer; a conserving agent; a neutralizer agent and purified water.
Also, it is the object of the present invention to provide a process of manufacture of a gel that contains pirfenidone for its cutaneous application.
Another objective of the present invention is to provide a gel medicine to be used as an anti-fibrotic and anti-inflammatory agent.
Composition of the Gel
The composition of the gel contains from 2 to 12% of Pirfenidone is elaborated utilizing from 0.4 to 1.2% of a viscous agent, from 10 to 30% of a solubilizer, from 5 to 15% of a non ionic solubilizer, from 0.2 to 1% of a conserving agent, from 0.4 to 1.2% a neutralizer agent and the rest of purified water. The viscous agent is selected from a carbomer 940 (MR); Carbomer Homopolymer Type A, cellulose derivatives; gums; poloxamers, ethyl alcohol and propylene glycol; the conserving agent is selected from a group consisting of Diazolidinyl urea, iodopropynyl butylcarbamate; methylparaben and a mix of these compounds; the neutralizer agent is selected from a group of primary, secondary and tertiary aliphatic amines of the mono-, bi- and triethanolamine type, and of the hydroxide alkaline metals, such as sodium hydroxide.
An example of the composition of the gel is shown in the table 1:
The gel containing Pirfenidone is manufactured as follows:
A prepared composition according to procedure describe is shown in table 2.
These compositions are shown in an example mode, but they are not limited in any level of the reach of the description of the present invention.
Number | Date | Country | Kind |
---|---|---|---|
MX/A/2007/009796 | Aug 2007 | MX | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/MX2008/000107 | 8/14/2008 | WO | 00 | 4/28/2010 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2009/022899 | 2/19/2009 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4376118 | Daher et al. | Mar 1983 | A |
5811130 | Boettner et al. | Sep 1998 | A |
5958420 | Jenson | Sep 1999 | A |
6365131 | Doshi et al. | Apr 2002 | B1 |
20040029946 | Arora et al. | Feb 2004 | A1 |
Number | Date | Country |
---|---|---|
0016775 | Mar 2000 | WO |
2004073713 | Sep 2004 | WO |
Entry |
---|
International Search Report for Application No. PCT/MX2008/000107, dated Dec. 9, 2008. |
Number | Date | Country | |
---|---|---|---|
20110224265 A1 | Sep 2011 | US |